Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

CAPR Investor Alert: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) for Potential Securities Fraud

accessnewswire.com
CAPR The article details an investigation into Capricor Therapeutics for potential securities fraud following a significant stock drop. Concerns were raised by FDA briefing documents regarding cardiac efficacy and statistical analysis plan changes for their drug Deramiocel, leading to a sharp decline in CAPR shares.

CAPR Investor Alert: Levi & Korsinsky Investigates Capricor Therapeutics, Inc. (CAPR) for Potential Securities Fraud NEW YORK CITY, NY / ACCESS Newswire / July 29, 2026 / Levi & Korsinsky notifies investors that it has commenced an investigation into Capricor Therapeutics, Inc. ("Capricor Therapeutics, Inc.") (NASDAQ:CAPR) concerning potential violations of the federal securities laws.

Capricor Therapeutics, Inc. shareholders were hit with a 60% to 70% drop on July 27, 2026, after FDA briefing documents for Deramiocel raised significant concerns with cardiac efficacy and a post-randomization statistical analysis plan change.

The FDA briefing documents were released ahead of the July 29, 2026 advisory committee meeting. FDA staff stated that Deramiocel had not demonstrated sufficient effectiveness on the cardiac endpoint and described a statistical analysis plan change after randomization. CAPR shares fell sharply the same day.

Before the drop, Capricor had framed the FDA review and cardiac data in positive terms. On March 12, 2026, CEO Linda Marbán said the FDA had not identified potential review issues in communications with the Company. On May 7, 2026, Capricor stated that Deramiocel slowed cardiac decline by approximately 91% compared to placebo with statistical significance.

If you suffered a loss on your Capricor Therapeutics, Inc. securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

Ed Korsinsky, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (212)363-7500

Fax: (212)363-7171

SOURCE: Levi & Korsinsky, LLP